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Abstract
The QFix EncompassTM stereotactic radiosurgery (SRS) immobilization system consists
of a thermoplastic mask that attaches to the couch insert to immobilize patients trea-
ted with intracranial SRS. This study evaluates the dosimetric impact and verifies a
vendor provided treatment planning system (TPS) model in the Eclipse TPS. A thermo-
plastic mask was constructed for a Lucy 3D phantom, and was scanned with and with-
out the EncompassTM system. Attenuation measurements were performed in the Lucy
phantom with and without the insert using a pinpoint ion chamber for energies of
6xFFF, 10xFFF and 6X, with three field sizes (2 9 2, 4 9 4, and 6 9 6 cm2). The mea-
surements were compared to two sets of calculations. The first set utilized the vendor
provided Encompass TPS model (EncompassTPS), which consists of two structures: the
Encompass and Encompass base structure. Three HU values for the Encompass (200,
300, 400) and Encompass Base (600, 500, 400) structures were evaluated. The
second set of calculations consists of the Encompass insert included in the external
body contour (EncompassEXT) for dose calculation. The average measured percent
attenuation in the posterior region of the insert ranged from 3.4%–3.8% for the 6xFFF
beam, 2.9%–3.4% for the 10xFFF, and 3.3%–3.6% for the 6X beam. The maximum
attenuation occurred at the region where the mask attaches to the insert, where atten-
uation up to 17% was measured for a 6xFFF beam. The difference between measured
and calculated attenuation with either the EncompassEXT or EncompassTPS approach
was within 0.5%. HU values in the EncompassTPS model that provided the best agree-
ment with measurement was 400 for the Encompass structure and 400 for the
Encompass base structure. Significant attenuation was observed at the area where the
mask attaches to the insert. Larger differences can be observed when using few static
beams compared to rotational treatment techniques.
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1 | INTRODUCTION
Intracranial stereotactic radiosurgery (SRS) is a treatment technique
used to deliver large doses of radiation to small targets in the cra-
nium in order to manage primary brain tumors, metastasis, or func-
tional diseases. Frameless mask-based systems have become popular
over the past decade since they are noninvasive; allowing for greater
patient comfort as well as the ability to fractionate treatments while
still retaining the immobilization accuracy of frame-based treat-
ments.1–3 Current frameless-based systems typically use a clam shell
style mask to immobilize the patient in order to provide submillime-
ter accuracy treatments to small intracranial lesions.4
Frameless systems use either extensions in which the mask sys-
tem extends off the patient support structure, or overlays in which
the mask system is attached and indexed to the carbon fiber patient
support structure. The QFix EncompassTM SRS immobilization sys-
tem, created by QFix (Avondale, PA, USA) consists of a couch insert,
and a thermoplastic mask attached to the raised component of the
insert. The geometry and design of the insert is unique in that high
density carbon fiber material surrounds the cranium, which may
interfere with the target area to be treated.
Several groups have demonstrated the importance of modeling
immobilization devices in the treatment planning system (TPS) to
limit their dosimetric impact, particularly on skin dose, dose distribu-
tion, and attenuation.5–11 A TPS model of the QFix Encompass insert
has been created and is available in the Eclipse TPS software, v15.5
(Varian Medical System, Palo Alto, CA, USA). The QFix Encompass
immobilization device is an integral part of the Varian HyperArcTM
High-definition radiotherapy automated SRS delivery workflow. The
immobilization device allows the patient to be located in space rela-
tive to the machine isocenter to ensure machine clearance and effi-
ciency during automated delivery. In this study, we evaluate the
dosimetric properties of the QFix EncompassTM system and quantify
the amount of attenuation through the system. The Hounsfield Unit
(HU) values of the couch model in the TPS were verified. Finally, we
evaluated the dosimetric consequences and robustness of the
system.
2 | MATERIALS AND METHODS
2.A | The QFix EncompassTM model
The QFix EncompassTM SRS immobilization system consists of two
parts: the Encompass insert and the clam shell style FiberplastTM
mask [Fig. 1(a)]. The Encompass insert is an immobilization device
that can be attached to or overlaid on the treatment couch. The
clam shell style mask consists of an anterior and posterior portion
which is customized for each patient during simulation. The
FiberplastTM mask is a low temperature thermoplastic that hardens
quickly, typically within 10 min. The mask is aligned to the insert
with acrylic pins and locked into place with adjustable shims.
To evaluate the CT numbers of the Encompass system, a mask
was made on the Lucy 3D QA phantom (Standard Imaging,
Middleton WI, USA). After the mask hardened, a CT scan was
acquired of the mask and Encompass insert using a Philips Brilliance
Big bore scanner (Philips, Netherlands), using our institution’s
intracranial SRS protocol. (120 kVp, 400 mAs, 1 mm slice thickness,
FOV = 350 mm, 512 9 512 Matrix). The HU values were evaluated
for all portions of the Encompass system.
The QFix EncompassTM insert is modeled in Eclipse TPS v15.5 as
a support structure. The Encompass TPS model is a simplified model
of the full Encompass system that does not include some portions of
the couch. The Encompass TPS model consists of two separate
structures: Encompass and Encompass Base. The “Encompass” struc-
ture includes the bulk portion of the carbon fiber U-shaped insert.
The “Encompass Base” structure includes the posterior region of the
insert system and is made up of a double-layered section with a hol-
low interior [Fig. 1(b)].
2.B | Phantom setup
Measurements were performed in a spherical, Lucy 3D QA phantom
(Standard Imaging, Middleton WI, USA) with a PTW Pinpoint ion
chamber (Freiburg, Germany), 0.015 cc active volume. The Lucy
phantom was immobilized by creating a custom mask in the Encom-
pass insert system [Fig. 1(a)]. A CT scan of the phantom and Encom-
pass insert was acquired using the SRS protocol. The scan was
imported into the TPS, where two image sets were generated based
on how the Encompass system was to be included for dose calcula-
tion.
The first image set was the Encompass TPS image set (Encom-
passTPS) which was contoured according to the vendor recommenda-
tions for incorporating the Encompass couch structure onto a
patient image set. This consists of contouring the entire Encompass
system in the external body contour, including the patient and mask.
The Encompass TPS model is inserted as a support structure, and
then removed from the external body contour using the Boolean
tool. The contouring procedure results in the external body contour
encompassing the patient and mask, and the Encompass insert as a
separate support structure [Fig. 1(d)]. This allows the dose calcula-
tion to take into account portions of the mask system that are cus-
tom to each patient and are not included in the couch structure.
The second image set was the Encompass external image set
(EncompassEXT) which was contoured according to our institution’s
policies and procedures, prior to availability of a couch model in the
TPS. The external body contour includes all portions of the Encom-
pass immobilization device [Fig. 1(c)]. The external was contoured
using the search body function in Eclipse (Lower Threshold:
700 HU, Fill all cavities (2-D All), Disconnect Radius [cm]: 0.50, Fill
all Cavities, Close openings Radius [cm]: 2.00, Smoothing Level: 1).
The final EncompassEXT image set included the Lucy phantom, mask,
and Encompass insert inside the external structure [Fig. 1(c)].
A third image set, Lucyonly, was generated from a CT scan of the
Lucy phantom by itself without the Encompass insert and imported
directly into the TPS. Measurements in Lucy phantom with and with-
out the Encompass insert were performed in various areas of the
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Encompass insert to quantify the amount of attenuation, which was
then compared with calculated values from the three image sets
above.
2.C | Attenuation measurements
Measurements were performed on a Varian EDGE linear accelerator
(Varian, Palo Alto, CA, USA) using three energies: a flattened 6 MV
beam (6X), and flattening filter free 6 MV (6xFFF) and 10 MV
(10xFFF) beams. The measurements were performed for each
energy, with three field sizes: 2 9 2, 4 9 4, and 6 9 6 cm2. A total
of 18 measurement setups were performed with and without the
Encompass insert. The Encompass and Lucy setups were aligned
using CBCT, matched to the TPS CT with 6 degrees of freedom.
A total of 41 measurements per energy and field size were per-
formed. The measurements were broken down into four zones (Fig. 2).
Zone 1 (blue) is a 70° area that represents the area of the “Encompass
Base” structure in the Eclipse Encompass TPS model. Zone 1 ranges
from gantry 140° to 220°, with measurements taken at increments of
5 or 10°. Zone 2 (green) is a 15° area and represents the transition
zone between the Encompass and Encompass base structures. Zone 2
ranges from 125–140° to 220–235°, with measurements taken in
increments of 2.5°. Zone 3 (yellow) is a region of 20° and represents
the solid portion of Encompass insert. Zone 3 ranges from 100–120°
to 240–260°, with measurements taken at increments of 10°. Zone 4
(red) spans a region of 12.5° in the area where the mask attaches to
the Encompass insert. Zone 4 ranges from 262.5–275° to 85–97.5°,
with measurements taken at 2.5° increments.
The measured percent attenuation, Attenmeasured, of the insert
was calculated as (1(DoseEncompass/DoseLucy))*100. Where
DoseEncompass is the dose measured in Lucy with the Encompass
insert and DoseLucy is the dose measured in the Lucy, without the
Encompass insert, under the same irradiation conditions.
2.D | Validation of HU Values for the Encompass
TPS Model
The HU values for the Encompass TPS model were determined for
each of the structures in the Encompass model by choosing the HU
that minimized the difference between the measured and calculated
percent attenuation in a specific zone. The HU value for the “Encom-
pass Base” structure was determined from measurements in Zone 1,
the region of double-layered carbon fiber. The measurements were
averaged and compared to the structure set HU values of 600,
500, and 400. Similarly, the HU value for the “Encompass” struc-
ture was determined by choosing the HU that minimized the differ-
ence between measured and calculated attenuation in Zone 3, the
region that consists of only the carbon fiber insert. HU values of 200,
300, and 400 were evaluated in this study.
The calculation of the percent attenuation was performed in the
Eclipse TPS v15.5 on the three image sets (EncompassTPS, Encom-
passEXT, and Lucyonly) for three energies and three field sizes using the
Anisotropic Analytical Algorithm v.15.5.02 with a grid size of 1.5 mm.
The percent attenuation of the Encompass TPS model, AttenCalc, was
calculated as (1(DoseEncompass/DoseLucy))*100. Where DoseEncompass
is the dose calculated to the ion chamber in the EncompassTPS image
F I G . 1 . (a) Encompass insert and
customized two pieces, clam shell style
mask made for a Standard Imaging Lucy
Phantom. (b) Axial cross-section of the
Lucy phantom in mask demonstrating the
two portions of the model: Encompass
(magenta) and the Encompass Base (cyan).
(c) EncompassEXT image set consisting of
the Encompass insert included in the
external contour for dose calculation. (d)
EncompassTPS image set consisting of the
phantom and mask contoured in the
external contour and the Encompass
treatment planning structure model.
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set and DoseLucy is the dose calculated to the ion chamber in the
Lucyonly image set under same calculation conditions.
To verify that all portions of the Encompass system were cor-
rectly modeled in the Encompass TPS model, the percent attenua-
tion was also calculated with the EncompassTPS and compared to
the percent attenuation calculated with the EncompassEXT image set.
2.E | Clinical case recalculation and measurement
Ten clinical cases were recalculated with the Encompass TPS model
(EncompassTPS) and compared to the clinical plan, where the Encom-
pass system was taken into account in the external contour (Encom-
passEXT). The targets in the ten clinical cases ranged in location as
well as in size. The treatment techniques included volumetric modu-
lated arc therapy (VMAT) and dynamic conformal arc (DCA); both
techniques are implemented for SRS treatments at our institution.
Table 1 summarizes the lesion location, size, and treatment tech-
nique for the 10 clinical cases recalculated.
The dose to 99% (PTVD99%), 95% (PTVD95%), and 0.035 cc
(PTVD0.035cc) of the PTV was evaluated between the clinical plan and
the same plan recalculated with the Encompass TPS model. For the
highest priority organ-at-risk, the dose to 0.035 cc (OARD0.035cc) was
evaluated. For the acoustic neuroma cases, the OAR with the high-
est priority is the cochlea. However, for a solitary metastasis with no
physiological OARs within a 2 cm radius, a 0.5 cm ring around the
PTV was created to simulate an OAR around the lesion. A paired
student t-test was used to evaluate the differences in PTV and OAR
dose between the two plans, where P < 0.05 was the threshold for
statistical significance.
The plans were measured in the Lucyonly setup and the Lucy in the
Encompass insert using a PTW Pinpoint ion chamber (Freiburg, Ger-
many), positioned at the isocenter. The measurements were performed
at full couch rotations to include different portions of the Encompass
mask system in the measurements. The difference between the
Lucyonly and Lucy in the Encompass insert setup was compared to eval-
uate the overall attenuation through the Encompass insert.
2.F | Couch placement sensitivity
The Encompass TPS model is manually registered and inserted on each
patient image set. To evaluate the dosimetric uncertainty of the place-
ment of the couch, the position of the couch model was intentionally
displaced 3 mm in the vertical, lateral and longitudinal directions. This
deviation was introduced to the Lucy phantom image set and the dif-
ference in dose to isocenter was evaluated between the intentional
deviation and the baseline image set. The couch deviation was also
applied to a patient image set, which showed the greatest discrepancy
in dose calculation between the EncompassTPS and EncompassEXT
images sets. For the patient data set, the dose to PTVD99%, PTVD95%,
PTVD0.035 cc, OARD0.035 cc, and point dose for each beam at isocenter
were compared.
3 | RESULTS
3.A | Attenuation
In Zones 1–3, the average percent attenuation measured, AttenMeasured,
for the 6xFFF beam was 3.8%, 3.6%, and 3.4%, for the 10xFFF beam
F I G . 2 . (Right) Axial cross-section of Lucy phantom demonstrating measurement zones used for HU validation. Zone 1 (blue), Zone 2 (green),
Zone 3 (yellow), and Zone 4 (red). (Left) Measured and calculated percent attenuation for EncompassTPS and EncompassEXT structure sets with
Zones 1–4 highlighted to demonstrate areas of high attenuation.
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3.4%, 3.1%, and 2.9% and for the 6X beam 3.6%, 3.4%, and 3.3%, for
field sizes of 2 9 2 cm2, 4 9 4 cm2, and 6 9 6 cm2, respectively. The
largest amount of attenuation occurs in Zone 4, in the area where the
mask attaches to the Encompass insert. The maximum attenuation
measured in Zone 4 for the 6xFFF beam was 17.0%, 15.8%, and 15.2%,
for the 10xFFF beam 12.7%, 12.3%, and 11.6% and for 6X beam 14.8%,
13.9%, and 13.7%, for field sizes of 2 9 2 cm2, 4 9 4 cm2, and
6 9 6 cm2, respectively. Table 2 summarizes the percent attenuation
measured for the three energies and field sizes measured.
The average difference between measured, AttenMeasured, and
calculated attenuation, AttenCalc, for the EncompassEXT with the
6xFFF beam was 0.1%, 0.1%, 0.1%, for the 10xFFF beam was
0.3%, 0.3%, 0.4%, and for the 6X beam 0.2%, 0.3%, 0.4%, for field
sizes of 2 9 2 cm2, 4 9 4 cm2, and 6 9 6 cm2, respectively. The
maximum difference between measured and calculated attenuation
with the EncompassEXT was 3.6% which occurred in Zone4 for the
6xFFF beam for a 2 9 2 cm2 field size.
3.B | HU validation
The HU values of the components of the Encompass systems are
summarized in Table 3. The final HU value chosen for the Encom-
passTPS was 400HU for the Encompass structure and 400 for the
Encompass base structure. This minimized the difference between
measured and calculated attenuation, (AttenCalc–AttenMeasured). The
percent difference between the measured and calculated attenua-
tion for the EncompassTPS for HU evaluation is summarized in
Table 4.
In Zones 1–3, the average difference between measured,
AttenMeasured, and calculated attenuation, AttenCalc, for the Encom-
passTPS for the 6xFFF beam was 0.3%, 0.2%, and 0.0%, for the
10xFFF beam 0.2%, 0.2%, and 0.3% and for 6X beam 0.1%, 0.2%, and
0.4%, for field sizes of 2 9 2 cm2, 4 9 4 cm2, and 6 9 6 cm2,
respectively. The maximum difference between measured and calcu-
lated attenuation with the EncompassTPS was 3.0% which occurred in
Zone4 for the 6X beam for a 6 9 6 cm2 field size. The percent differ-
ences are relatively similar in range to those obtained when dose was
calculated from HU values obtained directly from the CT in the
EncompassEXT calculations. Figure 2(b) shows the measured and
calculated percent attenuation from the EncompassEXT and
EncompassTPS.
3.C | Clinical case recalculation and measurement
The average difference in PTV coverage between the patient data
sets including the Encompass insert in the external with the TPS
TAB L E 1 Summary of location, number of fractions, total dose, treatment technique and target volume for the 10 clinical cases in the study
that were recalculated. Two plans treated two targets simultaneously, and the target volume for each target is shown. Percent difference in
isocenter dose between measured and calculated with only Lucy (Lucyonly) and with Lucy in the Encompass system (LucyENC are summarized).
Location Fractions
Total
dose
Treatment tech-
nique
Target volume
(cc)
Isocenter % difference,
Lucyonly
Isocenter % difference,
LucyENC
Lt Acoustic Neuroma 1 14 VMAT 0.32 3.6% 4.7%
Lt Cerebellar + Lt
Temporala
1 18 VMAT 5.71, 7.96 0.5% 1.7%
Rt Parietal 1 18 DCA 0.16 0.5% 0.2%
Rt Frontal 1 18 DCA 0.23 0.2% 1.1%
Rt Acoustic Neuroma 1 13 VMAT 6.75 0.5% 0.2%
Lt Frontal 1 18 DCA 0.09 2.1% 0.2%
Lt Occipital 1 18 DCA 0.56 0.7% 1.1%
Rt Cavernous Sinus 3 24 VMAT 5.55 1.3% 2.0%
Lt Frontal 1 18 VMAT 14.0 1.6% 0.3%
Lt Cerebellara 1 18 VMAT 0.99, 0.04 2.1% 5.0%
aTwo lesions treated simultaneously with a single isocenter, dose measured at the center of larger of the two lesions.
TAB L E 2 Summary of the percent attenuation measured using a pinpoint ion chamber for 6X, 6xFFF, and 10xFFF photon energies for field
sizes of 2 9 2 cm2, 4 9 4 cm2, and 6 9 6 cm2. The average percent attenuation (minimum, maximum) values are shown for Zones 1–3 and
separately for Zone 4 where more attenuation is observed.
Field Size Location 6X 6xFFF 10xFFF
2 9 2 cm2 Zone 1–3 3.6% (2.9, 4.3%) 3.8% (3.2, 4.5%) 3.4% (2.8, 4.0%)
Zone 4 8.0% (2.2, 14.8%) 8.9% (2.3, 17.0%) 7.2% (1.9, 12.7%)
4 9 4 cm2 Zone 1–3 3.4% (2.6, 4.2%) 3.6% (2.8, 4.4%) 3.1% (2.5, 3.6%)
Zone 4 7.6% (2.1, 13.9%) 8.5% (1.8, 15.8%) 6.8% (2.1, 12.3%)
6 9 6 cm2 Zone 1–3 3.3% (2.5, 4.0%) 3.4% (2.6, 4.0%) 2.9% (2.4, 3.5%)
Zone 4 7.3% (1.9, 13.7%) 8.2% (2.0, 15.2%) 6.5% (1.8, 11.6%)
226 | SNYDER ET AL.
model for the ten patient plans for PTVD99% was 0.04% and
0.07% for PTVD95% for. The average difference to the maximum
dose PTVD0.035 cc was 0.08%. The average difference to the
OARD0.035 cc was 0.2%. No significant difference, P > 0.05, was
found between the two different image sets.
The absolute percent difference between the measurement with
and without the insert ranged from 1.9% to 2.9% (Table 1). The
average difference was 0.3% for all ten patients.
3.D | Couch placement sensitivity
In Zones 1–3, the average percent difference in dose calculated
on the Lucy when the Encompass insert TPS model was shifted
3 mm in the vertical, lateral, and longitudinal directions were
0.00%, 0.02%, 0.09%, respectively. The maximum difference
observed was 0.45, 0.30%, and 0.0% in the vertical, lateral, and
longitudinal directions, respectively. Whereas, the average differ-
ence in Zone 4 were 0.11%, 0.00%, and 0.12% when the TPS
model for the Encompass insert was shifted 3 mm in the vertical,
lateral, and longitudinal directions, respectively. The maximum dif-
ference was 3.19%, 0.34%, and 0.83% in the vertical, lateral, and
longitudinal directions, respectively. The greatest percent
difference in Zone 4 for all three translational directions was
observed at Gantry 270°.
With a 3 mm translation displacement of the Encompass insert
TPS model, the average difference for the clinical case recalculation
for PTVD99%, PTVD95%, PTVD0.035 cc, and OARD0.035 cc was 0.02%,
0.02%, 0.003%, and 0.1%, respectively. The average percent differ-
ence at isocenter for the three treatment beams was 0.04%, 0.00%,
and 0.07% for beam 1 at couch 0°, beam 2 at couch 280° and beam
3 at couch 40°, respectively. The maximum difference occurred at
beam3, couch 40° when the couch was shifted 3 mm laterally.
4 | DISCUSSION
A treatment planning system model of the QFix EncompassTM SRS
immobilization system was created as part of the HyperArcTM High-
definition radiotherapy automated SRS delivery workflow. The TPS
Encompass model is used to locate the patient in space relative to
the treatment isocenter to ensure machine clearance during auto-
mated treatment delivery. If the Encompass insert is used indepen-
dent of the HyperArcTM workflow, it is not necessary to insert the
couch model. However, to reduce dose calculation uncertainty due
to areas of high attenuation, the Encompass insert should be
included in the external contour. Areas of high attenuation, up to
17%, were observed in the region where the customized mask
attaches to the Encompass insert which can impact the dose distri-
bution if not considered in the dose calculation.
The magnitude of calculated attenuation between the Encom-
passEXT and EncompassTPS was similar. Differences in Zones 1 can
be attributed to the way the Encompass base is modeled in the TPS
model (Fig. 2). The base layer of the Encompass insert consists of a
double layer of high-density carbon fiber with a hollow center. The
base layer was modeled as a solid piece due to the difficulty of mod-
eling a thin layer of material in the TPS and transferring the
TAB L E 3 Summary of components of the QFix EncompassTM SRS
immobilization system, corresponding HU value ranges, and whether
the component is included in the Encompass TPS model.
HU Range Included in TPS Model
Insert (frame) 150 to 450 Yes (Encompass)
Insert (inner layer) 900 to 950 Yes (Encompass Base)
Alignment Pins 50 to 85 No
Clips 35 to 95 No
Adjustable Shims 450 to 50 No
Mask 30 to 150 No
TAB L E 4 Evaluation of HU values for Encompass Insert and Base structures for the Encompass TPS model. The percent difference between
measured and calculated attenuation is shown for 6xFFF, 10xFFF, and 6X for field sizes of 2 9 2 cm2, 4 9 4 cm2, and 6 9 6 cm2. HU values
of 200, 300, 400 were evaluated for the frame structure and 600, 500, 400 for the base structure.
Encompass insert (HU) Encompass base (HU)
6xFFF 200 300 400 600 500 400
2 9 2 0.53%  0.28% 0.38%  0.28% 0.24%  0.35% 0.73%  0.50% 0.46%  0.45% 0.46%  0.45%
4 9 4 0.54%  0.41% 0.43%  0.40% 0.30%  0.44% 0.83%  0.51% 0.53%  0.44% 0.08%  0.44%
6 9 6 0.65%  0.27% 0.53%  0.30% 0.38%  0.30% 0.88%  0.42% 0.61%  0.40% 0.01%  0.36%
10xFFF 200 300 400 600 500 400
2 9 2 0.85%  0.24% 0.77%  0.24% 0.60%  0.29% 1.18%  0.41% 0.94%  0.40% 0.40%  0.41%
4 9 4 0.74%  0.19% 0.63%  0.19% 0.53%  0.23% 0.95%  0.39% 0.74%  0.19% 0.27%  0.37%
6 9 6 0.69%  0.37% 0.60%  0.41% 0.49%  0.41% 1.00%  0.33% 0.78%  0.30% 0.33%  0.29%
6X 200 300 400 600 500 400
2 9 2 0.77%  0.28% 0.65%  0.33% 0.52%  0.33% 1.06%  0.40% 0.84%  0.33% 0.27%  0.43%
4 9 4 0.79%  0.40% 0.71%  0.41% 0.58%  0.43% 1.06%  0.35% 0.84%  0.30% 0.27%  0.33%
6 9 6 0.97%  0.36% 0.83%  0.39% 0.70%  0.39% 1.10%  0.41% 0.89%  0.34% 0.37%  0.34%
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structure to subsequent patient image sets. Due to this, the Encom-
pass base layer HU value is effectively an average of the Encompass
insert (400) and air (1000). Due to an increase in equivalent path
length when traversing a larger portion of the high density insert at
an oblique angle, compared to the perpendicular entry through the
base structure, the differences are accentuated when the base is
modeled with only one material. The HU value of 400 was chosen
for the Encompass base structure in order to minimize the average
difference in Zone 1, which more closely match the attenuation
through the oblique angles. If the attenuation was matched more
closely at Gantry 180, the difference in attenuation at the oblique
angles would increase. Differences in Zone 4 can be attributed to
the difficulty and inherent inaccuracy in measuring and calculating
dose for small fields in areas of heterogeneity.12,13 Zone 4 includes
portions of the insert, mask, adjustable shims and acrylic pins. The
maximum difference in measured and calculated attenuation was
within 5%, which is within the uncertainty between measured and
calculated dose found in previous studies.9,13,14
It is important to include areas of high attenuation in the beam
path to be included in the dose calculation. The TPS model is regis-
tered manually which may lead to potential errors in placement of
the couch model. With a 3 mm translation shift in the vertical, longi-
tudinal, and lateral directions, a maximum difference of 3% was
observed for a static beam at gantry 270 through the clips and
shimming system of the mask. The difference in couch shift was
minimized in the actual treatment plan that consists of several non-
coplanar arcs. This minimizes the amount and regions of the higher
density insert that the primary beam passes through. The sensitivity
of the couch setup is very dependent on the location of the lesion,
couch and gantry angles and what the treatment beam traverses. On
the recalculated clinical plan, the percent change was within 1%;
however, this can change depending on where the location of the
lesion is relative to the high density portions of the insert [Fig. 3(a)].
Depending on the couch angle, the change in isocenter dose varies
between beams. During the SRS planning process, arc geometry is
typically chosen to achieve conformal dose distributions rather than
to avoid portions of the mask that are more attenuating. However,
for static fields, such as IMRT or 3D conformal techniques, care
should be taken to avoid areas of high attenuation since the dosi-
metric consequences can be accentuated. Figure 3(b) demonstrates
an example of whole brain opposed lateral radiotherapy treatment
for a patient initially simulated for an SRS treatment. Areas of high
attenuation occur at the clip area, resulting in decreased coverage to
the brain. The patient was ultimately treated with whole brain using
a hippocampal sparing VMAT technique.
In this study, the anisotropic analytical algorithm (AAA) was used
to verify the HU values of the TPS model. For AAA, inaccuracies in
dose calculation have been demonstrated at the interfaces of materi-
als.13,14 In the Encompass mask system, dose inaccuracies can occur
between the mask, insert, and air. However beyond the interface
region, dose from AAA is often comparable to Monte Carlo based
algorithms, within 2%–4%.15 Other studies have also found that
couch models included in the external body contour for dose calcula-
tion often agree with measurements within 2%.5,9,11
A limitation of this study is that skin dose was not evaluated.
Because the mask is an integral part of the Encompass system and is
customized for each patient, the mask acts as additional build up and
the amount may vary from patient to patient. Also, for rotational type
techniques such as DCA or VMAT, dose to the skin is often spread out
across the arc path length. Furthermore, the largest dosimetric differ-
ences occurred at gantry 270 through the shimming system of the
mask. The change in attenuation when the shimming level is adjusted
was not evaluated, and may change as air gaps are introduced in the
system. Future studies could be performed evaluating the dose to skin,
as well as the impact of shimming level, static treatment fields as well
as using more accurate algorithms such as Monte Carlo.
5 | CONCLUSION
Significant attenuation occurs when using the QFix EncompassTM
SRS immobilization system, and occurs at the area where the mask
attaches to the insert. HU values for the Encompass TPS model
were found to be 400 for the Encompass structure and 400 for
the Encompass base structure, which resulted in an average percent
difference between measured and calculated attenuation of less than
0.5%. Small uncertainties in couch placement do not significantly
perturb the dose calculation. However, larger differences can be
seen when using few static beams compared to rotational treatment
techniques.
F I G . 3 . (a) Coronal cross-section of
clinical patient recalculated with
translational shifts demonstrating
sensitivity of positioning of beams relative
to high density portions of the Encompass
insert (magenta). (b) Axial cross-section of
two field, opposed lateral beams for whole
brain radiotherapy treatment
demonstrating areas of high attenuation
through the clips resulting in decreased
coverage to the brain.
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